The midterm result of drug coated balloon with paclitaxel for the treatment of TASC C/D superficial femora-popliteal artery disease
10.3760/cma.j.issn.1007-631X.2019.11.009
- VernacularTitle: 药物涂层球囊治疗股腘动脉TASC C/D级病变的中期结果
- Author:
Xin JIA
1
;
Wei GUO
1
;
Xiaoping LIU
1
;
Jiang XIONG
1
;
Xiaohui MA
1
;
Hongpeng ZHANG
1
;
Yongle XU
1
Author Information
1. Department of Vascular and Endovascular Surgery, PLA General Hospital, Beijing l00853, China
- Publication Type:Journal Article
- Keywords:
Peripheral arterial diseases;
Arteries;
Drug coated balloon
- From:
Chinese Journal of General Surgery
2019;34(11):944-947
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety and efficacy of the drug coated balloon(DCB) for complex TASC C/D superficial femora-popliteal artery diseases.
Methods:Patency, target lesion revascularization (TLR) rate, clinical improvement and safety endpoints of femora-popliteal lesions in 68 patients from PLA General Hospital treated with DCB were retrospectively analyzed from June 2016 to June 2018. The mean age of the patients were (72.7±13.2) years old. Rutherford categories were from 2 to 5, and ABI baseline were 0.56±0.22.
Results:There were 76 limbs treated by DCB in total in this study. Mean lesion length was (26.7±15.3) cm. 73.6% of lesions were totally occluded, 26.4% were of stenosis and 61.8% were highly calcified. Stent implantation was performed in 36.8% cases. Kaplan Meier estimates of primary patency were 74.2%±7.6% and 67.7%±6.4% at 1 and 2 years, respectively, whereas freedom from TLR was 81.4%±5.1% and 73.6%±5.4%. ABI were 0.83±0.16 at 1 year, and 0.79±0.24 at 2 years. Major amputation rate was 2.9% and mortality rate was 2.9% and 4.4% at 1 year and 2 years respectively. Diabetes, highly calcification, renal insufficiency and re-stenotic lesions were identified as predictors of restenosis.
Conclusions:DCB are safe and effective in delaying restenosis in complex TASC C/D superficial femora-popliteal artery disease as found by midterm follow-up.
